Table 1:
Study characteristics of included studies
| Author (ref) | Year of publication | Study population | Transplant characteristics | Outcomes |
|---|---|---|---|---|
| Anderson23 | 1997 | 13 patients median age: 40 (R: 18–49) Primary/Secondary MF: 62%/38% DIPSS int-2/high: not reported |
Conditioning: 100% MAC Donor source: 62% MRD; 8% MMRD; 23% MUD; 8% haplo GVHD prophylaxis: 92% CsA/MTX; 8% MTX |
Survival: 2-year OS: 77% RFS/EFS/PFS/DFS: not reported GVHD: aGVHD: 548% (15% grade III/IV); cGVHD: 46% (46% extensive) Graft failure: total 0% |
| Guardiola30 | 1999 | 55 patients median age: 42 (R: 4–53) Primary MF: 100% DIPSS int-2/high: not reported |
Conditioning: 100% MAC Donor source: 89% MRD; 6% MMRD; 6% MUD GVHD prophylaxis: 78% CsA/MTX; 7% CsA/MTX/steroid; 9% T-cell depletion; 15% other |
Survival: 5-year OS: 47%; 1-year NRM: 27% RFS/EFS/PFS/DFS: not reported GVHD: aGVHD: 60% (33% grade III/IV); cGVHD: 60% (36% extensive) Graft failure: total 9.1% (9.1% primary; secondary not reported) |
| Daly26 | 2003 | 25 patients median age: 49 Primary/Secondary MF: 76%/24% DIPSS int-2/high: not reported |
Conditioning: not reported Donor source: 52% MRD; 8% MMRD; 40% MUD GVHD prophylaxis: 100% CsA/MTX |
Survival: 2-year OS: 41%; 1-year NRM: 48% RFS/EFS/PFS/DFS: 2-year PFS: 37% GVHD: aGVHD: 52% (16% grade III/IV); cGVHD: 59% (35% extensive) Graft failure: total 9.1% (9.1% primary; secondary not reported) |
| Kerbauy37 | 2007 | 104 patients median age: 49 (R: 18–70) Primary/Secondary MF: 66%/29% DIPSS int-2/high: not reported |
Conditioning: 91% MAC, 9% nonmyeloablative Donor source: 53% MRD; 4% MMRD; 35% MUD; 9% MMUD GVHD prophylaxis: 86% CsA/MTX; 10% CsA/MMF; 5% other |
Survival: 5-year OS: 61%; 5-year NRM: 34% RFS/EFS/PFS/DFS: not reported GVHD: aGVHD: 64% (21% grade III/IV); cGVHD: 84% (59% extensive) Graft failure: total 6.9% (primary not reported; 6.9% secondary) |
| Patriaca44 | 2008 | 100 patients median age: 49 (R: 21–68) Primary/Secondary MF: 82%/18% DIPSS int-2/high: not reported |
Conditioning: 48% MAC, 52% RIC Donor source: not reported GVHD prophylaxis: 70% CsA/MTX; 10% CsA; 2% CsA/MMF; 18% CsA/MTX/ATG |
Survival: 1-year OS: 59%; 1-year NRM: 35%; 5-year OS: 31% RFS/EFS/PFS/DFS: 5-year RFS: 28% GVHD: aGVHD: 41%; cGVHD: 43% (11% extensive) Graft failure: total 12.0% (12.0% primary; secondary not reported) |
| Kroger60 | 2009 | 103 patients median age: 55 (R: 32–68) Primary/Secondary MF: 61%/39% DIPSS int-2/high: not reported |
Conditioning: 100% RIC Donor source: 32% MRD; 68% MUD GVHD prophylaxis: 100% CsA/MTX |
Survival: 5-year OS: 67%; 1-year NRM: 16% RFS/EFS/PFS/DFS: 5-year DFS: 51% GVHD: aGVHD: 27% (11% grade III/IV); cGVHD: 49% (24% extensive) Graft failure: total 1.9% (1.9% primary; secondary not reported) |
| Alchalby21 | 2010 | 162 patients median age: 56 (R: 32–73) Primary/Secondary MF: 65%/35% DIPSS int-2/high: not reported |
Conditioning: 100% RIC Donor source: not reported GVHD prophylaxis: not reported |
Survival: 5-year OS: 62%; 1-year NRM: 22% RFS/EFS/PFS/DFS: 5-year DFS: 46% GVHD: aGVHD: 22% (6% grade III/IV); cGVHD: 38% (20% extensive) Graft failure: total 12.3% (4.3% primary; 8.0% secondary) |
| Bacigalupo24 | 2010 | 46 patients median age: 51 (R: 24–67) Primary MF: 100% DIPSS int-2/high: not reported |
Conditioning: 100% RIC Donor source: 65% MRD; 4% MMRD; 30% MUD GVHD prophylaxis: 100% CsA/MTX |
Survival: 5-year OS: 45%; 5-year NRM: 24% RFS/EFS/PFS/DFS: not reported GVHD: aGVHD: 37%; cGVHD: 30% (30% extensive) Graft failure: not reported |
| Nagi42 | 2011 | 11 patients median age: 51 (R: 46–62) Primary/Secondary MF: 55%/45% DIPSS int-2/high: not reported |
Conditioning: 100% RIC Donor source: 18% MRD; 55% MUD; 27% MMUD GVHD prophylaxis: 100% CsA/alemtuzumab |
Survival: 2-year OS: 46%; 2-year NRM: 54% RFS/EFS/PFS/DFS: not reported GVHD: aGVHD: 27%; cGVHD: 9% (9% extensive) Graft failure: total 9.1% (9.1% primary; secondary not reported) |
| Abelsson20 | 2012 | 92 patients median age: not reported Primary/Secondary MF: 76%/24% DIPSS int-2/high: not reported |
Conditioning: 44% MAC, 54% RIC Donor source: 51% MRD; 49% MUD GVHD prophylaxis: not reported |
RIC cohort: 5-year OS: 59%; 28% aGVHD (11% grade III/IV) MAC cohort: 5-year OS: 49%; aGVHD: 76% (17% grade III/IV) Graft failure: total 14.1% (14.1% primary; secondary not reported) |
| Ditschkowski27 | 2012 | 76 patients median age: 51 (R: 22–67) Primary/Secondary MF: 62%/38% DIPSS int-2/high: 25% |
Conditioning: 59% MAC; 41% RIC Donor source: 36% MRD; 4% MMRD; 43% MUD; 17% MMUD GVHD prophylaxis: 61% CsA/MTX; 22% CsA/ATG; 17% CsA/alemtuzumab |
Survival: 5-year OS: 53%; 1-year NRM: 26% RFS/EFS/PFS/DFS: 5-year RFS: 50% GVHD: aGVHD: 31% (12% grade III/IV); cGVHD: 54% (24% extensive) Graft failure: total 5.3% (4.0% primary; 1.3% secondary) |
| Nivison-Smith43 | 2012 | 57 patients median age: 47 (R: 16–71) Primary/Secondary MF: 86%/14% DIPSS int-2/high: not reported |
Conditioning: 32% MAC; 68% RIC Donor source: 32% MRD; 68% MUD GVHD prophylaxis: 38% CsA/MTX; 18% CsA/MTX/steroid; 6% CsA/MMF; 35% other; 7% none |
Survival: 1-year OS: 72%; 5-year OS: 58%; 1-year NRM: 25% RFS/EFS/PFS/DFS: 5-year DFS: 57% GVHD: aGVHD: 37% Graft failure: total 12.3% (12.3% primary; secondary not reported) |
| Scott48 | 2012 | 170 patients median age: 51.5 (R: 12–79) Primary/Secondary MF: 59%/40% DIPSS int-2/high: 60% |
Conditioning: 89% MAC; 11% RIC Donor source: 51% MRD; 2% MMRD; 39% MUD; 11% MMUD GVHD prophylaxis: 78% CsA/MTX; 7% CsA/MTX/steroid; 9% T-cell depletion; 14.5% other |
Survival: 1-year OS: 74%; 5-year OS: 57%; 1-year NRM: 26% RFS/EFS/PFS/DFS: 5-year RFS: 57% GVHD: aGVHD: 68% (18% grade III/IV); cGVHD: 63% (55% extensive) Graft failure: total 7.2% (2.4% primary; 4.8% secondary) |
| Hussein36 | 2013 | 8 patients median age: 0.7 (R: 0.1–1.5) Primary MF: 100% DIPSS int-2/high: not reported |
Conditioning: 100% MAC Donor source: 50% MRD; 12.5% MUD; 25% MMUD; 12.5% haplo GVHD prophylaxis: 75% CsA/MTX; 25% CsA/MMF |
Survival: 5-year OS: 100% RFS/EFS/PFS/DFS: 5-year RFS: 100% GVHD: aGVHD: 50% (13% grade III/IV); cGVHD: 63% (25% extensive) Graft failure: total 0% |
| Gupta31 | 2014 | 233 patients median age: 55 (R: 19–79) Primary MF: 100% DIPSS int-2/high: 38% |
Conditioning: 100% RIC Donor source: 48% MRD; 5% MMRD; 19% MUD; 13% MMUD; 13% UC GVHD prophylaxis: 53% CsAbased; 45% Tac-based; 2% other |
Survival: 1-year OS: 62%; 5-year OS: 47%; 1-year NRM: 18% RFS/EFS/PFS/DFS: 5-year PFS: 27% GVHD: aGVHD: 37% (19% grade III/IV); cGVHD: 51% Graft failure: total 16.0% (16.0% primary; secondary not reported) |
| Robin46 | 2014 | 35 patients median age: 54 (R: 28–63) Primary/Secondary MF: 57%/43% DIPSS int-2/high: 49% |
Conditioning: 100% RIC Donor source: 100% UC GVHD prophylaxis: 97% calcineurin inhibitor-based |
Survival: 2-year OS: 44%; 2-year NRM: 35% RFS/EFS/PFS/DFS: 2-year EFS: 30% GVHD: aGVHD: 29% (9% grade III/IV); cGVHD: 39% (6% extensive) Graft failure: total 40.0% (not differentiated) |
| Shanavas49 | 2014 | 27 patients median age: 61 (R: 30–70) Primary/Secondary MF: 63%/34% DIPSS int-2/high: 82% |
Conditioning: 26% MAC; 74% RIC Donor source: 59% MRD; 30% MUD; 11% MMUD GVHD prophylaxis: 74% CsA/MMF; 19% CsA/alemtuzumab; 4% CsA/MMF/alemtuzumab; 4% CsA/MMF/ATG |
Survival: 1-year OS: 77%; 2-year OS: 56%; 1-year NRM: 23% RFS/EFS/PFS/DFS: 2-year PFS: 46% GVHD: aGVHD: 48% (12% grade III/IV); cGVHD: 66% Graft failure: total 0% |
| Slot50 | 2015 | 53 patients median age: 60 (R: 36–69) Primary/Secondary MF: 64%/36% DIPSS int-2/high: 44% |
Conditioning: 36% nonmyeloablative; 64% RIC Donor source: 34% MRD; 42% MUD; 15% MMUD; 7% UC GVHD prophylaxis: 4% CsA; 56% CsA/MMF; 11% CsA/mycophenolic acid; 6% CsA/steroid; 16% CsA/MMF/steroid; 2% mycophenolic acid; 2% none |
Survival: 2-year OS: 49%; 2-year NRM: 43% RFS/EFS/PFS/DFS: not reported GVHD: aGVHD: 63%; cGVHD: 49% Graft failure: total 28.3% (22.6% primary; 5.7% secondary) |
| Shanavas55 | 2016 | 100 patients median age: 59 (R: 32–72) Primary/Secondary MF: 57%/43% DIPSS int-2/high: 54% |
Conditioning: 44% MAC; 56% RIC Donor source: 36% MRD; 50% MUD GVHD prophylaxis: not reported |
Survival: 2-year OS: 61%; 2-year NRM: 28% RFS/EFS/PFS/DFS: not reported GVHD: aGVHD: 37% (16% grade III/IV); cGVHD: 48% (23% extensive) Graft failure: total 8.0% (4.0% primary; 4.0% secondary) |
| Kroger35 | 2017 | 169 patients median age: 58 (R: 18–75) Primary/Secondary MF: 65%/27% DIPSS int-2/high: 73% |
Conditioning: 2% MAC; 98% RIC Donor source: 21% MRD; 49% MUD; 30% MMUD GVHD prophylaxis: not reported |
Survival: 5-year OS: 56%; 1-year NRM: 28% RFS/EFS/PFS/DFS: 5-year PFS: 48% Graft failure: not reported |
| Lestang39 | 2017 | 34 patients median age: 57 (R: 41–66) Primary/Secondary MF: 65%/35% |
Conditioning: 82% MAC; 15% RIC Donor source: 42% MRD; 39% MUD; 12% MMUD; 7% UC GVHD prophylaxis: not reported |
Survival: 5-year OS: 52%; 2-year NRM: 30% RFS/EFS/PFS/DFS: 5-year PFS: 40% GVHD: aGVHD: 41% (9% grade III/IV); cGVHD: 42% (27% extensive) Graft failure: total 10.0% (10.0% primary; secondary not reported) |
| Wolschke53 | 2017 | 136 patients median age: 58 (R: 32–75) Primary/Secondary MF: 66%/29% |
Conditioning: 100% RIC Donor source: 19% MRD; 49% MUD; 32% MMUD GVHD prophylaxis: not reported |
Survival: 5-year OS: 60% RFS/EFS/PFS/DFS: not reported GVHD: aGVHD: 38% (18% grade III/IV) Graft failure: not reported |
| Abd Kadir19 | 2018 | 159 patients median age: 59 (R: 28–74) Primary/Secondary MF: 68%/32% DIPSS int-2/high: 68% |
Conditioning: 31% MAC; 69% RIC Donor source: 15% MRD; 54% MUD; 31% MMUD GVHD prophylaxis: 18% CsA/MTX; 75% CsA/MMF; 1% Tac/MMF; 5% other |
Survival: 2-year OS: 86%; 2-year NRM: 23% RFS/EFS/PFS/DFS: 2-year PFS: 62% GVHD: not reported Graft failure: total 4.4% (3.1% primary; 1.3% secondary) |
| Kuykendall38 | 2018 | 17 patients median age: 62 (R: 42–72) Primary/Secondary MF: not reported DIPSS int-2/high: 83% |
Conditioning: not reported Donor source: not reported GVHD prophylaxis: not reported |
Survival: 2-year OS: 67% RFS/EFS/PFS/DFS: not reported GVHD: not reported Graft failure: not reported |
| Tefferi52 | 2018 | 67 patients median age: 55 (R: 19–68) Primary/Secondary MF: 64%/36% DIPSS int-2/high: 79% |
Conditioning: 18% MAC; 82% RIC Donor source: 45% MRD; 46% MUD GVHD prophylaxis: 45% Tac/MTX+/−ATG; 22% Tac/MMF/ATG; 30% CsA/MTX |
Survival: 5-year OS: 62% RFS/EFS/PFS/DFS: not reported GVHD: aGVHD: 68%; cGVHD: 44% (33% moderate/severe) Graft failure: total 4.5% (4.5% primary; secondary not reported) |
| Ali22 | 2019 | 110 patients median age: 55 (R: 29–72) Primary/Secondary MF: 53%/43% DIPSS int-2/high: 52% |
Conditioning: 100% RIC Donor source: 46% MRD; 40% MUD; 14% MMUD GVHD prophylaxis: 91% Tac/sirolimus-based; 4% Tac-based; 5% CsA/MMF-based |
Survival: 5-year OS: 65%; 5-year NRM: 17% RFS/EFS/PFS/DFS: 5-year PFS: 60% GVHD: aGVHD: 45% (17% grade III/IV); cGVHD: 59% extensive Graft failure: total 1.8% (1.8% primary; secondary not reported) |
| Barabanshikova57 | 2019 | 20 patients median age: 51 (R: 32–64) Primary/Secondary MF: 65%/35% DIPSS int-2/high: not reported |
Conditioning: 100% RIC Donor source: 15% MRD; 55% MUD; 10% MMUD; 20% haplo GVHD prophylaxis: 100% PTCy/ruxolitinib |
Survival: 2-year OS: 85%; 2-year NRM: 15% RFS/EFS/PFS/DFS: 2-year EFS: 72% GVHD: aGVHD: 25% (25% grade III/IV); cGVHD: 40% (20% extensive) Graft failure: total 15.0% (15.0% primary; secondary not reported) |
| Barabanishikova25 | 2019 | 8 patients median age: not reported Primary/Secondary MF: not reported DIPSS int-2/high: not reported |
Conditioning: 100% RIC Donor source: 25% MRD; 38% MUD; 38% haplo GVHD prophylaxis: 100% PTCy |
Survival: 2-year OS: 90% RFS/EFS/PFS/DFS: not reported GVHD: aGVHD: 38% (25% grade III/IV); cGVHD: 13% (0% extensive) Graft failure: total 12.5% (12.5% primary; secondary not reported) |
| Gagelmann28 | 2019 | 159 patients median age: 59 (R: 33–75) Primary/Secondary MF: 0%/100% DIPSS int-2/high: 53% |
Conditioning: 16% MAC; 84% RIC Donor source: 37% MRD; 63% MUD GVHD prophylaxis: not reported |
Survival: 2-year OS: 61% RFS/EFS/PFS/DFS: not reported GVHD: not reported Graft failure: not reported |
| Gupta61 | 2019 | 21 patients median age: 59 (R: 39–70) Primary/Secondary MF: 48%/52% DIPSS int-2/high: 76% |
Conditioning: 100% RIC Donor source: 33% MRD; 67% MUD GVHD prophylaxis: 100% calcineurin inhibitor +/− ATG |
Survival: 2-year OS: 63%; 2-year NRM: 28% RFS/EFS/PFS/DFS: 2-year PFS: 59% GVHD: aGVHD: 57% (14% grade III/IV); cGVHD: 76% (19% extensive) Graft failure: total 14.3% (4.8% primary; 9.5% secondary) |
| Helbig32 | 2019 | 44 patients median age: 49 (R: 14–67) |
Conditioning: 2% MAC, 98% RIC Donor source: 43% MRD; 57% MUD |
Survival: 2-year OS: 54% RFS/EFS/PFS/DFS: not reported |
|
Primary/Secondary MF: 68%/32% DIPSS int-2/high: 84% |
GVHD prophylaxis: 100% CsA/MTX +/− ATG |
GVHD: aGVHD: 47% (7% grade III/IV); cGVHD: 36% Graft failure: total 2.3% (2.3% primary; secondary not reported) |
||
| Mannina40 | 2019 | 18 patients median age: 59 (R: 43–67) Primary/Secondary MF: 78%/22% DIPSS int-2/high: 72% |
Conditioning: 33% MAC, 67% RIC Donor source: 39% MRD; 50% MUD; 11% MMUD GVHD prophylaxis: not reported |
Survival: 5-year OS: 84% RFS/EFS/PFS/DFS: 5-year RFS: 84% GVHD: aGVHD: 72% (11% grade III/IV); cGVHD: 50% (6% moderate) Graft failure: 0% |
| McLornan41 | 2019 | 2224 patients (14–43 RIC and 781 MAC) median age: 57.5 (RIC) and 52.8 (MAC) Primary/Secondary MF: 65%/35% (RIC) and 83%/17% (MAC) DIPSS int-2/high: not reported |
Conditioning: 35% MAC, 65% RIC Donor source: not reported GVHD prophylaxis: not reported |
Survival: 5-year OS: 51% for RIC and 53% for MAC; 1-year NRM: 26% for RIC and 25.5% for MAC RFS/EFS/PFS/DFS: not reported GVHD: not reported Graft failure: total 12.0% (12.0% primary; secondary not reported) |
| Raj45 | 2019 | 56 patients median age: 57 (R: 38–72) Primary/Secondary MF: 75%/25% DIPSS int-2/high: not reported |
Conditioning: 70% MAC, 30% RIC Donor source: not reported GVHD prophylaxis: 79% PTCy, 21% other |
Survival: 2-year OS: 56%; 2-year NRM: 38% RFS/EFS/PFS/DFS: 2-year RFS: 43% GVHD: aGVHD: 28% (9% grade III/IV); cGVHD: 42% (6% extensive) Graft failure: total 22.0% (9.0% primary; 13.0% secondary) |
| Salas47 | 2019 | 37 patients median age: 60 (R: 18–69) Primary/Secondary MF: not reported DIPSS int-2/high: 76% |
Conditioning: 100% RIC Donor source: 24% MRD; 46% MUD; 11% MMUD, 19% haplo GVHD prophylaxis: 100% CsA/PTCy/ATG |
Survival: 2-year OS: 66%; 1-year NRM: 23% RFS/EFS/PFS/DFS: 2-year RFS: 50% GVHD: aGVHD: 35% (11% grade III/IV); cGVHD: 27% (22% extensive) Graft failure: total 16.2% (not differentiated) |
| Tamari51 | 2019 | 101 patients median age: 59 (R: 30–73) Primary/Secondary MF: 61%/28% DIPSS int-2/high: 56% |
Conditioning: 18% MAC, 82% RIC Donor source: 46% MRD; 52% MUD GVHD prophylaxis: not reported |
Survival: 2-year OS: 61%; 5-year OS: 52%; 2-year NRM: 26% RFS/EFS/PFS/DFS: 2-year RFS: 56% GVHD: not reported Graft failure: not reported |
| Gowin29 | 2020 | 551 patients median age: 51 (R: 20–69) Primary/Secondary MF: 84%/16% DIPSS int-2/high: 34% |
Conditioning: 51% MAC, 7% nonmyeloablative, 41% RIC Donor source: 38% MRD; 47% MUD; 15% MMUD GVHD prophylaxis: not reported |
Survival: 5-year OS: 55% RFS/EFS/PFS/DFS: not reported GVHD: not reported Graft failure: not reported |
| Hernandez-Boluda33 | 2020 | 197 patients median age: 58 (R: 52–62) Primary/Secondary MF: 56%/22% DIPSS int-2/high: 74% |
Conditioning: 33% MAC, 67% RIC Donor source: 43% MRD; 1% MMRD; 32% MUD; 13% MMUD; 9% haplo, 3% UC GVHD prophylaxis: 54% CsAbased, 40% Tac-based; 6% sirolimus-based; 28% PTCy; 24% ATG |
Survival: 5-year OS: 51%; 1-year NRM: 27% RFS/EFS/PFS/DFS: not reported GVHD: aGVHD: 55% (23% grade III/IV); cGVHD: 40% (20% extensive) Graft failure: total 5.1% (not differentiated) |
| Hernandez-Boluda34 | 2020 | 2916 patients median age: 56 Primary/Secondary MF: 74%/26% DIPSS int-2/high: 61% |
Conditioning: 35% MAC, 65% RIC Donor source: 37% MRD; 63% MUD GVHD prophylaxis: not reported |
Survival: 5-year OS: 50%; 1- NRM: 26% RFS/EFS/PFS/DFS: not reported GVHD: aGVHD: 46% (14% grade III/IV); cGVHD: 42% (24% moderate) Graft failure: total 11.1% (not differentiated) |
| Lwin56 | 2020 | 142 patients median age: 56 (R: 26–69) Primary/Secondary MF: 66%/34% DIPSS int-2/high: 58% |
Conditioning: 17% MAC, 83% RIC Donor source: 52% MRD GVHD prophylaxis: 57% CsA/MTX; 15% CsA/MTX/steroid; 9% CsA or tac + MMF; 16% other |
Survival: 5-year OS: 57%; 1-year NRM: 25% RFS/EFS/PFS/DFS: 5-year PFS: 44% GVHD: aGVHD: 21% (9% grade III/IV); cGVHD: 29% (18% moderate) Graft failure: total 12.7% (6.3% primary; 6.3% secondary) |
| Morozova59 | 2020 | 20 patients median age: 51 (R: 32–64) Primary/Secondary MF: 70%/30% DIPSS int-2/high: 90% |
Conditioning: 100% RIC Donor source: 15% MRD; 55% MUD; 10% MMUD; 20% haplo GVHD prophylaxis: 100% PTCy + ruxolitinib |
Survival: 2-year OS: 85%; 2-year NRM: 15% RFS/EFS/PFS/DFS: 2-year EFS: 72% GVHD: aGVHD: 25% (15% grade III/IV); cGVHD: 40% (20% moderate) Graft failure: total 5.0% (5.0% primary; secondary not reported) |
| Salit58 | 2020 | 28 patients median age: 56 (R: 34–68) Primary/Secondary MF: 54%/46% DIPSS int-2/high: 58% |
Conditioning: 82% MAC, 18% RIC Donor source: 50% MRD GVHD prophylaxis: Tac + MTX or MMF |
Survival: 2-year OS: 86% RFS/EFS/PFS/DFS: not reported GVHD: aGVHD: 70% (15% grade III/IV); cGVHD: 35% (29% moderate/severe) Graft failure: total 0% |
| Yoon54 | 2020 | 35 patients median age: 55 (R: 34–72) Primary/Secondary MF: 77%/23% DIPSS int-2/high: 100% |
Conditioning: 100% RIC Donor source: 46% MRD; 29% MUD; 14% MMUD; 11% haplo GVHD prophylaxis: CsA or tac + MTX +/− ATG |
Survival: 2-year OS: 60%; 2-year NRM: 30% RFS/EFS/PFS/DFS: not reported GVHD: aGVHD: 54% (34% grade III/IV); cGVHD: 46% (33% moderate) Graft failure: total 2.9% (0% primary; 2.9% secondary) |
aGVHD – acute graft-versus-host disease; ATG – anti-thymocyte globulin; cGVHD – chronic graft-versus-host disease; CsA – cyclosporin A; DFS – disease-free survival; EFS – event-free survival; haplo – haploidentical; MAC – myeloablative conditioning; MF – myelofibrosis; MMF – mycophenolate mofetil; MMRD – mismatched related donor; MMUD – mismatched unrelated donor; MRD – matched related donor; MTX – methotrexate; MUD – matched unrelated donor; NRM – non-relapse mortality; OS – overall survival; PTCy – post-transplant cyclophosphamide; R – range; RFS – relapse-free survival; RIC – reduced intensity conditioning; Tac – tacrolimus; UC – umbilical cord